Elevation Oncology Inc. (ELEV)
NASDAQ: ELEV
· Real-Time Price · USD
0.34
-0.00 (-0.03%)
At close: May 02, 2025, 12:48 PM
Company Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.
The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Elevation Oncology Inc.
| Country | United States |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Joseph J. Ferra Jr. |
Contact Details
Address: 888 Seventh Avenue New York, New York United States | |
| Website | https://elevationoncology.com |
Stock Details
| Ticker Symbol | ELEV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783032 |
| CUSIP Number | 28623U101 |
| ISIN Number | US28623U1016 |
| Employer ID | 84-1771427 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joseph J. Ferra Jr. | Chief Executive Officer, President & Director |
| Robert C. Yang | Senior Vice President & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Filing |
| Apr 24, 2025 | DEF 14A | Filing |
| Apr 16, 2025 | SCHEDULE 13D | Filing |
| Apr 04, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 4 | Filing |